NRAS and melanoma: To determine whether vemurafenib and dabrafenib had differential effects upon the growth of BRAF‐ and NRAS‐mutant melanoma cells, we treated 1205Lu (BRAF mutant) and WM1366 cells (NRAS mutant) chronically (>14 days) with each drug and performed cell counts (Fig. 1A).